What is Leerink Partnrs' Forecast for TNDM FY2025 Earnings?

Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) - Equities research analysts at Leerink Partnrs issued their FY2025 EPS estimates for Tandem Diabetes Care in a note issued to investors on Monday, July 14th. Leerink Partnrs analyst M. Kratky anticipates that the medical device company will post earnings per share of ($1.30) for the year. The consensus estimate for Tandem Diabetes Care's current full-year earnings is ($1.68) per share. Leerink Partnrs also issued estimates for Tandem Diabetes Care's FY2027 earnings at ($0.01) EPS.

Several other brokerages also recently commented on TNDM. Wall Street Zen downgraded Tandem Diabetes Care from a "hold" rating to a "sell" rating in a research report on Saturday, June 21st. Stifel Nicolaus decreased their price objective on Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Mizuho started coverage on shares of Tandem Diabetes Care in a report on Thursday, April 10th. They issued a "neutral" rating and a $20.00 target price on the stock. Citigroup reaffirmed a "sell" rating and set a $14.00 price target (down from $24.00) on shares of Tandem Diabetes Care in a report on Wednesday, July 9th. Finally, Piper Sandler dropped their target price on shares of Tandem Diabetes Care from $36.00 to $30.00 and set an "overweight" rating for the company in a research note on Thursday, May 1st. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Tandem Diabetes Care currently has a consensus rating of "Hold" and an average target price of $32.71.

Tandem Diabetes Care Stock Performance

Shares of TNDM stock traded down $0.59 during trading on Wednesday, reaching $14.77. The company had a trading volume of 1,684,780 shares, compared to its average volume of 1,504,319. The company has a market capitalization of $983.83 million, a PE ratio of -5.31 and a beta of 1.48. The company has a debt-to-equity ratio of 1.99, a current ratio of 2.30 and a quick ratio of 1.81. The firm's 50 day simple moving average is $19.61 and its two-hundred day simple moving average is $23.75. Tandem Diabetes Care has a one year low of $14.66 and a one year high of $47.60.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.07). The firm had revenue of $234.42 million for the quarter, compared to analyst estimates of $220.19 million. Tandem Diabetes Care had a negative net margin of 18.71% and a negative return on equity of 57.33%. The firm's quarterly revenue was up 22.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.65) earnings per share.

Institutional Investors Weigh In On Tandem Diabetes Care

A number of hedge funds have recently modified their holdings of the business. AlphaQuest LLC grew its holdings in shares of Tandem Diabetes Care by 138.7% in the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock valued at $34,000 after acquiring an additional 541 shares in the last quarter. Assetmark Inc. increased its holdings in Tandem Diabetes Care by 42.9% during the first quarter. Assetmark Inc. now owns 1,750 shares of the medical device company's stock worth $34,000 after buying an additional 525 shares during the last quarter. NBC Securities Inc. acquired a new stake in Tandem Diabetes Care in the first quarter valued at $37,000. Jones Financial Companies Lllp grew its position in shares of Tandem Diabetes Care by 195.8% in the 4th quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock valued at $41,000 after acquiring an additional 748 shares during the period. Finally, Brooklyn Investment Group increased its stake in shares of Tandem Diabetes Care by 417.8% during the 1st quarter. Brooklyn Investment Group now owns 3,397 shares of the medical device company's stock worth $65,000 after purchasing an additional 2,741 shares during the last quarter.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.